A randomized, multicenter, double-blind, group-sequential study to evaluate the efficacy, immunogenicity, and safety of a single dose of V710 in adult patients scheduled for cardiothoracic surgery is currently underway (http://clinicaltrials.gov/ct2/show/NCT00518687).gov/ct2/show/NCT00518687
n=8) or placebo (n=8) in a double blind parallel group design.
Methods: This was a double blind, independent group design study of the effects of acute oral doses of FNZ in young healthy volunteers.
Design Double blind, parallel group, randomised, placebo controlled trial.
Prospective, randomised, double blind, parallel group, placebo controlled 3 year trial.
Design Double blind parallel group randomised controlled trial with six months' follow-up conducted May 2011-March 2013.
This double blind parallel group randomised controlled trial was conducted in Germany.
In a 16-week, multicenter, randomized, double blind, parallel-group study, mitiglinide administration with pioglitazone monotherapy improved glycemic control in 381 Japanese patients with type 2 diabetes [ 100].
The trial is a prospective, double blinded, parallel-group controlled trial with balanced randomisation [1: 1].
The study design was prospective and double blind with parallel groups.
Design Double blind, placebo controlled, parallel group, multicentre, randomised controlled trial.
